Close Menu

Investing in Biotech

Randal Kirk, one of the only billionaires to make his money from investing in biotech, says his new synthetic biology company, Intrexon, will be the biggest thing he has ever done, says Forbes' Robert Langreth and Matthew Herper. The company is working on protein-based drugs, gene therapy, industrial enzymes, and ag-bio.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new Trump executive order about "free inquiry" on college campuses may threaten $35 billion-worth of federal research funding, reports Ars Technica.

As we enter conference season, Nature News asks why graduate students and postdocs are sometimes forced to choose between paying the rent and paying to attend important meetings.

A new analysis says that a 2018 study claiming to show biparental mtDNA inheritance has several flaws.

In PNAS this week: a genome sequence analysis of Crucihimalaya himalaica, multicellularity and fruiting body development in mushroom-forming fungi, and more.